PRNewsWire
10 Jul 2026, 00:58 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
AstraZeneca's Phase III CARDIO-TTRansform trial for the drug Wainua failed to meet its primary endpoint of statistically significant benefit on CV mortality and recurrent CV events. — The failure of a Phase III trial for a key value driver directly impacts future revenue projections and pipeline viability.
-0.80Wainua was positioned as a critical component of AstraZeneca's stated $80 billion revenue ambition for 2030. — The loss of a primary driver for a long-term financial target suggests a significant gap in achieving company-wide growth goals.
-0.60AstraZeneca shares fell more than 8.3% in early trading following the trial failure announcement. — Immediate market devaluation confirms investor disappointment and an adjustment of the company's current valuation.
-0.40Continue reading
6 related stories
Top 2 movers · tap to explore
Law firm Levi & Korsinsky has launched a securities investigation into AstraZeneca regarding potentially misleading statements related to the drug's potential. — Pending securities litigation creates additional legal risk and potential financial liabilities for the company.
-0.30Which stocks this story touches
The company's key Phase III trial missed its primary endpoint, leading to an 8.3% share price drop and a securities fraud investigation.
Shares fell more than 20% following the disclosure of a Phase-3 trial failure and a subsequent securities investigation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
6h ago
